The U.S. House of Representatives and the Senate have both incorporated the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT Act), championed by the CF Foundation, as part of a legislative package to reauthorize the U.S. Food and Drug Administration's (FDA) system for evaluating new prescription drugs and devices.
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
|
5 min read
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
|
3 min read
The CF Foundation’s “Adding Tomorrows” Video Selected From More Than 1,000 entries; To Be Featured on YouTube’s Homepage
|
3 min read
On March 8, more than 40 Cystic Fibrosis Foundation volunteers from across the nation came together on Capitol Hill to speak out on behalf of their friends and family members with cystic fibrosis.
|
2 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
|
1 min read
The Cystic Fibrosis Foundation today applauds the Food and Drug Administration's approval of Kalydeco™ (ivacaftor; previously known as VX-770), a major advance in the search for a cure for cystic fibrosis.
|
3 min read
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
|
5 min read